International Cancer & Immuno-Oncology Conference 2026

Sandrine Lacombe, after a PhD in chemical-physics, she conducted early research at the Fritz Haber Institute of the Max Planck Society under Nobel Laureate Professor G. Ertl. She later served as invited professor at the Sherbrooke University Hospital (Canada) and received an International Research Collaboration Award from the University of Sydney (Australia). Her research focuses on advancing particle therapy using theranostic nanoparticles. She contributed to 93 publications, supervised 11 PhDs. She currently direct the interdisciplinary center for innovative radiation therapies, iNanoTheRad. Former Vice-President for International Affairs of U.Paris-Saclay, she also offer her expertise to other institutions for the development of international and European strategies.

Dr. Pietro Salvatori graduated at the University of Florence Medical School, Italy. He earned specialization in General Surgery, Otorhinolaryngology, and Maxillo-Facial Surgery. He was Research Fellow at the University of Liverpool, served in several Institutions, and ended his hospital career as Head of ENT-H&N Department of the Humanitas San Pio X Hospital, Milan, Italy. At present, Dr. Salvatori acts as freelance Head & Neck Surgeon. Most of both his work and research dealt with head and neck cancer. Dr. Salvatori published more than 50 papers. During recent pandemic, he made research with international colleagues and published on ethanol inhalation to treat SARS-CoV-2 infection and Covid-19.

Stephan Bodis began his medical studies in 1978 at the University of Fribourg in Switzerland and completed them in 1984 at the University of Basel. He has held various roles including Director of the Institute of Radiation Oncology at the Aarau Cantonal Hospital and Associate Professor at the University of Zurich.

Dr. Shilpa S. Dhar is an Assistant Professor in GI Medical Oncology at MD Anderson Cancer Center and a faculty member at UTHealth Graduate School of Biomedical Sciences. Her research focuses on epigenetic regulation in gastrointestinal cancers, particularly gastric adenocarcinoma (GAC), with key discoveries on histone modifiers, such as KMT2D. Driven personally by her family's experience with GAC, she integrates molecular biology and translational research, utilizing mouse models, spatial transcriptomics, and epigenomics. Dr. Dhar has authored several high-impact publications and is a dedicated mentor to trainees at all levels.